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Abstract
Microalgae are thought to offer great potential as expression system for various industrial, therapeutic and diagnostic
recombinant proteins as they combine high growth rates with all benefits of eukaryotic expression systems. Moreover,
microalgae exhibit a phototrophic lifestyle like land plants, hence protein expression is fuelled by photosynthesis, which is
CO2-neutral and involves only low production costs. So far, however, research on algal bioreactors for recombinant protein
expression is very rare calling for further investigations in this highly promising field. In this study, we present data on the
expression of a monoclonal human IgG antibody against the Hepatitis B surface protein and the respective antigen in the
diatom Phaeodactylum tricornutum. Antibodies are fully-assembled and functional and accumulate to 8.7% of total soluble
protein, which complies with 21 mg antibody per gram algal dry weight. The Hepatitis B surface protein is functional as well
and is recognized by algae-produced and commercial antibodies.
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Introduction
Microalgae have been used in health food and cosmetic industry
for a long time as they represent a natural source of lipids, vitamins,
pigments and antioxidants [1]. The high oil content of certain
species makes them additionally interesting for the biofuel industry
as alternative to fossil fuels [2,3,4]. In recent years, microalgae came
into biotechnical focus for yet another reason as they might show
great potential as bioreactors for large-scale production of
recombinant proteins. Microalgae combine high growth rates like
prokaryotic cells with all advantages of eukaryotic expression
systems, i.e. post-transcriptional and post-translational modifica-
tions and the assembly of multimeric protein complexes. Moreover,
algae have a phototropic lifestyle hence their cultivation is CO2-
neutral and involves comparatively low costs only – a great
advantage to so far used expression systems like bacteria, yeast and
mammalian or insect cells [1,5,6]. Diatoms like Phaeodactylum
tricornutum are a group of algae with great ecological relevance as
they are responsible for up to 20% of global CO2-fixation and are
one of the most important sources of biomass in the oceans
contributing to about 40% of marine primary production [7,8]. In
addition, diatoms represent an important source of lipids and
silicate making them interesting for various biotechnological
applications e.g. in biofuel industry, food industry and nanofabrica-
tion [9]. Moreover, a recent publication showed that a genetically
manipulated diatom can produce the bioplastic PHB very efficiently
[10]. Despite this progress in diatom biotechnology, however,
diatoms have not been employed for expression of recombinant
proteins with biotechnological relevance, hitherto.
Monoclonal antibodies are important tools in medical therapy,
diagnostics and research and are mainly produced in mammalian
cell lines, since the establishment of hybridoma technology in 1975
[11]. As cultivation of mammalian cells is very cost-intense,
though, alternative expression systems are aspired and were tested
in the past. Such include bacterial systems for the expression of
antibody fragments as well as yeast, insect cells and transgenic
plants [12,13,14,15]. So far, however, none of these systems was
able to substitute established mammalian expression systems with
most critical limitations being low antibody expression levels, none
or species-specific glycosylation, which is a critical factor for
human therapy, or high production costs. Recently, a full-length
IgG antibody was synthesized in the chloroplast of the green alga
Chlamydomonas reinhardtii demonstrating that antibody expression in
an algal system is feasible [16]. This finding certainly should entail
further research, since algal systems show great potential as
photosynthesis fuelled bioreactors for large-scale expression of
therapeutic proteins like antibodies [17].
Vaccines are essential to prevent all kinds of severe infections,
however high production costs limit vaccination especially in
developing countries. The heterologous expression of antigen
based vaccines is in most of the cases less complicated than
antibody production, as eukaryotic expression systems are -
depending on the respective protein - not necessarily required.
However, the synthesis of antigens with complex post-translational
modifications still needs cost-intensive mammalian expression
systems bearing additionally a risk of human pathogenic
contaminations. In this respect, microalgae offer great prospects
as they are no host for human pathogens and combine fast growth
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28424rates with all advantages of eukaryotic expression systems. Once
appropriate bioreactors are established, cultivation involves only
low costs as light and water is almost all that is needed.
Hepatitis B is one of the most widespread viral infections with
worldwide over 350 million people being chronic carriers [18].
Chronic Hepatitis B causes hepatic cirrhosis and hepatocellular
carcinoma making an inexpensive therapy and vaccines essential
[19]. A vaccine consisting of the Hepatitis B surface antigen
(HBsAg) is available since 1982 and was formally isolated from
high-titer patients. Today, HBsAg vaccine is produced in yeast
[20,21], but production and processing costs are still very high.
In this study, we present data on the synthesis of a fully-
assembled and functional antibody against the Hepatitis B Virus
surface protein in the diatom P. tricornutum. Furthermore, we
demonstrate for the first time that the expression of the respective
antigen is feasible in a microalgal expression system. Altogether,
our studies highlight the enormous potential of a very efficient low
cost and CO2-neutral expression system, which offers fast growth
rates without the risk of human pathogenic contaminations.
Results
Expression of a fully-assembled human IgG antibody
against HBsAg in P. tricornutum
The human monoclonal IgG1 antibody CL4mAb from cell-line
TAPC301-CL4 recognizes the Hepatitis B surface antigen
(HBsAg) and was selected for heterologous expression in P.
tricornutum as it was already successfully expressed in other systems
like tobacco and bacteria [22,23]. Gene sequences for light and
heavy chain (LC/HC) were adapted to P. tricornutum specific
codon-usage and expressed as GFP fusion proteins in P. tricornutum.
In vivo localization studies demonstrated that both antibody chains
are expressed in the algal system and accumulate within the
endoplasmic reticulum (Fig. 1). For expression of complete
antibodies a co-transfection with sequences for both antibody
chains was performed. An ER-retention signal (DDEL) was added
at the C-terminus to avoid formation of complex glycosylation
patterns within the Golgi apparatus, which might be a drawback
in therapeutic applications [24]. In a small scale screening 12
independent transfectants were analysed for HC and LC
expression by Western Blot analyses with an antibody against
human IgG. Different transfectants showed slightly varying
expression levels of HC and LC (Fig. 2A). For further analyses,
the transfectant cell line with the highest expression level was
selected and antibody assembly was inspected by non-reducing
SDS-PAGE and Western Blot analyses. In contrast to reduced
SDS-PAGE light and heavy chain were not detected separately
but as high molecular weight signal of ,160 kDa suggesting
complete antibody assembly (Fig. 2B).
Antibody quantification, purification and in vitro
functionality analyses
For controlled expression of recombinant proteins in P.
tricornutum an inducible system based on the nitrate reductase
promoter/terminator was recently established with protein
expression being easily controlled via NH4
+/NO3
2 supplements
in the media [25]. Antibody expression was performed under
inducible conditions to find best induction periods and circumvent
potential growth defects due to over-expression. Best induction
period turned out to be 1–2 days. After that time point antibody
expression levels were significantly reduced (Fig. 2C). Interestingly,
constant antibody expression by providing nitrate from the very
beginning resulted in a high expression level similar to rates after
1–2 days (Fig. 2C). This demonstrates in addition that antibody
accumulation does not impair growth rate and cell viability – a
quite important attribute if large scale production is intended.
Quantification analyses demonstrated that antibody concentra-
tion lies at about 8.7% of total soluble protein on average. In
absolute data this complies with approximately 400 mg antibody in
a 250 ml culture, which needs about one week to reach adequate
cell density. Antibody production in P. tricornutum was tested over
13 month with no decrease in antibody expression levels, thus
antibody production seems to be stable for long terms. In general,
P. tricornutum transfection has proven to be stable and because
antibody expression is controlled by an inducible system –
allowing non-induced stock preservation - there should be no
problem with long-term stability of the production strains.
Antibody purification was carried out with protein A-Sepharose
beads in small scale. Purification was very efficient with no
contamination products or degradation products detected by
Coomassie or Silver Staining (Fig. 2D). Further analyses revealed
that both antibody chains get glycosylated in P. tricornutum as
Figure 1. In vivo localization studies on antibody heavy and light chain expression in P. tricornutum. Localization studies demonstrate
that heavy chain (HC) and light chain (LC) of the human IgG antibody CL4mAb fused to GFP accumulate in the endoplasmic reticulum of P.
tricornutum. Hence, the endogenous signal peptide is sufficient to direct both antibody chains into the ER in the algal system. Scale bar represents
10 mm. PAF – plastid autofluorescence.
doi:10.1371/journal.pone.0028424.g001
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lectins or subsequent oxidation with sodium-periodate, respective-
ly (Fig. 2D).
Functionality of a-HBsAg antibodies produced in P. tricornutum
was tested by ELISA. Wells were coated with Hepatitis B virus
surface antigen and incubated with serially diluted purified
antibody or whole protein extract of an antibody expressing
clone, respectively. Thereby it was demonstrated that a-HBsAg
antibodies produced in P. tricornutum are functional in vitro and
reach a binding maximum at a concentration of 100 ng/ml
(Fig. 3). Assays without antigen or with wild type protein extract
served as negative control.
Expression of the Hepatitis B virus surface antigen
(HBsAg) in P. tricornutum
The sequence of the Hepatitis B virus surface antigen (subtype
adr) was adapted to P. tricornutum specific codon-usage and
expressed as GFP fusion to check expression and localization in
the algal system. In vivo localization studies demonstrate that the
HBsAg GFP fusion proteins accumulate in several punctual
structures within the cell. Co-localization studies with an ER
resident membrane protein fused to CFP revealed that these
structures are partially located within the ER as expected because
of the N-terminal endogenous signal anchor sequence of HBsAg
(Fig. 4). Additional punctual GFP accumulations might be due to
the formation of virus like particles (VLP), which were observed in
other expression systems like CHO cells [26], yeast [20,21,27] and
also in plants [28,29,30].
For functionality analyses HBsAg was expressed without GFP
but with an ER retention signal, which has shown to enhance
HBsAg accumulation in plants [31]. Best induction time for
HBsAg expression turned out to be 2 days with HBsAg expression
levels of 0.7% of total soluble protein on average.
Combined analyses on functionality of antibodies and
antigens expressed in P. tricornutum
Inhibitory ELISA was used to combine tests on in vitro
functionality of antigen and antibody both being synthesized in
Figure 2. Analyses on antibody expression and assembly in P. tricornutum.A .Twelve independent P. tricornutum transfectants were
screened for expression of heavy and light chain of the antibody. Western Blot analyses demonstrate that expression levels are very similar. For
further analyses clone number 12 was selected as expression seems to be slightly enhanced. B. Western Blot analyses demonstrate that both
antibody chains are expressed in P. tricornutum cells and assemble into complete antibodies. Under reduced conditions both antibody chains are
detected separately, whereas in non-reduced SDS-PAGE a high molecular weight signal is detected, which corresponds to the fully-assembled
antibody. C. Monoclonal antibodies are expressed under a NO3
2-inducible promoter and different induction periods were tested to get highest
expression levels. Best induction period turned out to be 1–2 days (lane 2+3), which was interestingly similar to expression levels with constant
induction from the very beginning (lane 7). D. Antibodies expressed in P. tricornutum were purified using protein A-Sepharose beads. 5% of the
eluate was loaded on a SDS-PAGE demonstrating that purification is very efficient with no contaminations detected by Coomassie or Silver Staining.
Western Blot analyses with subsequent incubation with the lectin ConA revealed that both antibody chains get glycosylated in the ER of P.
tricornutum. ConA – Concanavalin A, d – days.
doi:10.1371/journal.pone.0028424.g002
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purified and incubated with serially diluted protein extract of
HBsAg expressing cells to check on antibody potency for
neutralizing HBV. Subsequently, the antigen/antibody mixture
was added to HBsAg coated wells and antibody binding efficiency
was measured. HBsAg expressed in P. tricornutum inhibited
antibody binding proportional to antigen concentration even
more effective than the positive control, which was commercially
available HBsAg produced in S. cerevisiae (Fig. 5). In conclusion, the
antibodies as well as the antigen expressed in P. tricornutum have
proven to be fully functional in vitro.
Discussion
Recombinant proteins are used in various industrial, therapeu-
tic and diagnostic applications and consequently there is a great
demand for expression systems involving low production costs.
Well-established systems that are currently used for the majority of
commercially available recombinant proteins are bacteria, yeast
and mammalian bioreactors, however each system brings different
limitations and the cost factor is still very high. Prokaryotic
expression systems lack the ability of post-transcriptional and post-
translation modifications, which are essential for the functionality
of many eukaryotic proteins [24]. Yeast is not suitable as
expression system for many mammalian proteins as multimeric
protein assembly does not occur and glycosylation is in many cases
incorrect [32]. Hence, mammalian systems still have to be used for
the synthesis of many recombinant proteins, even though the
expression level is low and mammalian bioreactors are difficult to
handle and are thus very expensive [33].
In the late 1980s plants came into biotechnological focus as
expression system for recombinant proteins, since they provide all
advantages of higher eukaryotic expression systems but are fuelled
by photosynthesis and hence do not need external carbon sources
[34,35,36]. Thus, protein expression in plants involves low
production costs and represents a CO2-neutral process. Another
advantage to mammalian cell lines is the absence of human
pathogenic contaminations making plants especially interesting for
the expression of pharmaceutical proteins like antibodies, vaccines,
hormones etc. [14,37,38,39]. Indeed many projects show prom-
ising potential with some antibodies for example having reached
clinical development stage (for review see Ref. 13). So far,
however, plants are not established as biotechnological expression
systems since protein expression levels and growth rates are still
too low to make plant-produced protein expression profitable.
Furthermore, plant-based expression systems depend on agricul-
tural areas and spreading of transgenic plants is difficult to control
shedding ethical concerns as well.
In this study, we tested the synthesis of an antibody and its
respective antigen in an algal expression system - the diatom P.
tricornutum. Microalgae provide all benefits of molecular farming in
plants but offer many additional advantages since cultivation and
handling is much easier and algae exhibit much higher growth
rates, i.e. algae need only a few days to reach the biomass obtained
Figure 3. ELISA with antibodies against the Hepatitis B surface protein expressed in P. tricornutum. ELISA assays with purified antibody
from P. tricornutum and whole cell extract of an antibody expressing clone demonstrate that algae-produced antibodies bind efficiently to
commercial HBsAg reaching a binding maximum at 100 ng/ml. There was no antibody binding without HBsAg coated to the wells (negative control)
or when using wild type protein extract (data not shown). Error bars indicate standard deviation (n=3). The typical result of three experiments is
shown.
doi:10.1371/journal.pone.0028424.g003
Figure 4. In vivo localization studies on Hepatitis B surface protein (HBsAg) expressed in P. tricornutum. HBsAg fused to GFP
accumulates in punctual patterns, which partially co-localize with an ER-membrane protein (Der1-2) that was expressed as CFP fusion. The ER in P.
tricornutum normally spans the whole cell, but is rather atypically aggregated in these clones. Punctual Fluorescence of HBsAg might be due to the
formation of virus like particles (VLPs). Scale bar represents 10 mm. PAF – plastid autofluorescence.
doi:10.1371/journal.pone.0028424.g004
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need agricultural areas but can be cultivated in special reactors like
closed systems or open ponds [41,42]. The results of this study
demonstrate that the human antibody CL.4mAb against the
Hepatitis B virus surface protein is expressed and assembled in
the endoplasmatic reticulum of P. tricornutum and accumulates to
approximately 8.7% of total soluble protein in two days of
induction. When expressed in Nicotiana tabacum the same antibody
reached much lower expression levels of only 0.2–0.6% in several
weeks [22], indicating that expression in the algal system is much
more efficient. Other antibodies against the Hepatits B virus
produced in plants showed low expression levels (0.5%) as well [43].
Nevertheless, it is important to note that in other studies plant
produced antibodies against different kinds of antigens reached
expression levels of 0.1–6.5% of total soluble protein depending on
various factors like plant species, plant organ, promoter choice,
targeting signals etc. (for review see Ref. 13). One frequent problem
with antibody expression in plants is rapid protein degradation
resulting in low antibody levels and many fragmented products
[44,45,46]. This does not seem to be a problem in P. tricornutum as
both antibody chains were prominent with almost no degradation
products being detected by Western Blot analyses. Antibody
purification with protein A-Sepharose was carried out without
problems, as neither antibody fragments, nor other contaminations
were detected by Coomassie or Silver Staining. Finally, ELISA
assays with whole protein extract as well as purified antibodies from
P. tricornutum demonstrated that the algal-produced antibody is
functional and binds the respective target antigen (HBsAg) very
efficiently in vitro. A binding maximum is reached at concentrations
comparable to the same antibody being expressed in N. tabacum and
in the parental mammalian cell line, respectively [22].
A full-length IgG antibody against the anthrax antigen PA83
was previously expressed in an algal system - the green alga C.
reinhardtii [16]. In this study, antibodies were expressed in the
chloroplast, showing that antibody assembly is feasible in this
formerly prokaryotic compartment as well. However, with 100 mg
purified protein per gram dry cells the antibody expression level
was not as efficient as in the ER of P. tricornutum were we found
expression levels of 21 mg antibody per gram algal dry weight. In
contrast to antibodies produced in the ER of P. tricornutum, the
chloroplast expressed antibodies remained aglycosylated as this
compartment lacks the respective equipment. Depending on the
application this can also be an advantage, though [16].
In addition to antibody synthesis we tested the expression of the
respective antigen, the Hepatitis B virus surface protein (HBsAg),
in P. tricornutum. The HBsAg is commonly used as vaccine against
Hepatitis B, however recombinant expression is complex and
needs cost-intense eukaryotic expression systems since disulfide-
bond formation as well as correct integration into the ER
membrane have to occur [47,48]. Again, plant-based bioreactors
came into focus and first studies on expression of HBsAg in plants
were performed in N. tabacum demonstrating that expression is
possible in a plant system [29]. Many studies with agricultural crop
like potato, banana and soybean confirmed that data and revealed
the potential of oral immunization [30,31,49,50]. Nevertheless,
low expression levels, long growth periods and the need of
agricultural areas prevented plant-based vaccination so far. In this
study, we could show for the first time that HBsAg expression is
possible in a microalgal system. HBsAg accumulated in P.
tricornutum to 0.7% of total soluble protein, which is more efficient
than in plant systems like N. tabacum showing expression levels of
only 0.01–0.05% of total soluble protein [28,29]. HBsAg expressed
in P. tricornutum is recognized by commercially antibodies as well as
by our algae-produced antibody as shown by ELISA and
inhibitory ELISA assays.
Altogether, microalgae certainly offer great potential as low cost
and CO2-neutral expression system for various recombinant
proteins used in industrial, therapeutic and diagnostic applications.
So far, however, only the green alga C. reinhardtii was employed for
initial biotechnical approaches and other model organisms still
need to be established. Our studies demonstrate that expression of
a full-length IgG antibody against the Hepatitis B surface protein is
very efficient in the diatom P. tricornutum with average expression
levels of 9% of total soluble protein. Moreover, we could show that
synthesis of complex antigens like the Hepatitis B surface protein is
feasible in P. tricornutum. Since diatoms are in focus of diverse
biotechnical applications like in fuel industry, food industry and
nanotechnology, they could be interesting for combined ap-
proaches for example as expression system for pharmaceutics with
lipids and silicate as side product.
Figure 5. Inhibitory ELISA using algae-produced HBsAg and the respective algae-produced antibodies. Purified Anti-HBsAg antibody
from P. tricornutum were mixed with serially diluted Hepatitis B surface protein (adr subtype) from P. tricornutum or S. cerevisiae (pos. control),
respectively. HBsAg expressed in P. tricornutum inhibits antibody binding to solid-phase antigen slightly stronger than commercially available HBsAg
from S. cerevisiae. Error bars indicate standard deviation (n=3). The typical result of four experiments is shown.
doi:10.1371/journal.pone.0028424.g005
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Plasmid construction
DNA sequences for light and heavy chain of the monoclonal
IgG1/kappa antibody CL4mAb (AF027158.2, AF027159.2) and
the HBsAg subtype adr (AF504292) were adapted to P. tricornutum
specific codon usage and synthesized by MrGene (Regensburg).
Sequences of the synthetic constructs have been deposited in
GenBankwithaccessionnumbers(JF970211,JF970210,JF970209).
For in vivo localization studies sequences were cloned in front of
eGFP into the vector pPha-NR, which is a derivate of pPhaT1 with
endogenous nitrate reductase promoter/terminator flanking the
multiple cloning site (JN180663). Co-localization studies of the
HBsAgGFPfusionproteinand theERwereperformed withthe ER
membrane protein hDer1-2 (XP_002181749) fused to CFP. For
expression of the fully-assembled antibody, DNA sequences for LC
and HC were cloned into the vector pPha-DUAL[26NR], which
contains two multiple cloning sites both under the control of the
endogenous nitrate reductase promoter (JN180664). For expression
of active HBsAg used for ELISA, the sequence was cloned into
pPha-NR without GFP fusion. To the C-terminus of antibody and
antigen sequences an ER retention signal (DDEL) was added.
P. tricornutum (Bohlin, University of Texas Culture Collection,
strain 646) was stably transfected by biolistic transfection as
described previously [51] using M10 tungsten particles and
1350 psi rupture discs together with the particle delivery system
Bio-Rad Biolistic PDS-1000/He. Cells were grown at 22uC under
continuous illumination (80 mmol photons per m
2 per s) on plates
containing solid f/2-medium with 1.3% agar and 1.5 mM NH4
+
as sole nitrogen source. Liquid cultures were grown with agitation
(150 rpm) in 150–1000 ml erlenmeyer flasks to a density of about
7610
6 cells/ml.
Expression and quantification of anti-HBsAg antibody
and HBsAg
P. tricornutum cultures were grown under non-induced conditions
in media containing 1.5 mM NH4
+ and were then transferred to
media containing 0.9 mM NO3
2 for 1–2 days to induce
expression of recombinant protein. For quantification of recom-
binant protein cells were harvested by centrifugation (5 min,
1.000 g) and resuspended in 5 ml buffer containing protease
inhibitor cocktail. For analyses of antibody expression a buffer
containing 0.1 M sodium phosphate pH 7.4 and 0.15 M NaCl
was used. For HBsAg quantification the buffer contained PBS
pH 7.2, 5 mg/ml sodium ascorbate, 10 mM EDTA and 0.1%
TritonX-100. Cells were disrupted using a French press
(20.000 psi cell pressure, five repeats) and cell debris was removed
by centrifugation (30 min, 20.000 g). For solubilization of HBsAg
the protein extract was incubated for 2 h with agitation before
removal of insoluble material. Total soluble protein was
determined by standard Bradford assays. For antibody quantifi-
cation the Easy-Titer human IgG (H+L) assay kit (ThermoScien-
tific) was used with human IgG as standard (550 ng/ml–17.2 ng/
ml). Total soluble protein extract or purified antibody was serially
diluted and antibody concentration was measured according to
manufacturer’s instructions. Wild type algal protein extract served
as negative control. To determine antibody portions per algal dry
weight a P. tricornutum culture was split with half of the cells being
lyophilized and weighted and half being used for quantification.
For quantification of HBsAg the Hepatitis B surface antigen
ELISA kit (Anogen) was used with HBsAg adr protein (Abcam) as
standard (550 ng/ml–34.4 ng/ml). Total soluble protein extract of
P. tricornutum transformants was serially diluted and HBsAg
concentration was determined according to manufacturer’s
instructions with wild type protein extract as negative control.
Purification of anti-HBsAg antibody
Protein extract of 250 ml P. tricornutum culture was prepared as
described above and incubated for 3 h at 4uC with 400 ml protein
A-Sepharose beads. After washing with purification buffer, anti-
HBsAg antibody was eluted with 0.2 M Glycin/HCl pH 2.5 and
neutralized with 1 M Tris/HCl pH 9. Purification and antibody
assembly was inspected by SDS-PAGE and Western Blot analyses
under reducing (5% b-mercaptoethanol) and non-reducing (no b-
mercaptoethanol) conditions. In Western Blot analyses biotin-
labelled anti- human IgG antibody was used and detected with
Streptavidin HRP. Glycosylation of antibody chains was checked
by incubation with ConA-HRP.
ELISA
ELISA plates were coated with 200 ng/well HBsAg subtype adr
(Abcam) in 50 mM NaHCO3 pH 8.3, washed with PBS+0.1%
Tween-20 and blocked with 1% BSA in PBS. After washing, 50 ml
serially diluted algal protein extract or purified antibody was
added for 2 h. Wells were washed again and incubated with HRP
coupled a-human IgG antibody for 1 h. After final washing bound
antibodies were detected using POD substrate. For inhibitory
ELISA plates were coated with HBsAg, washed and blocked as
described above. Protein extract of P. tricornutum cells expressing
HBsAg was serially diluted to HBsAg concentrations of 2 mg/ml–
62.5 ng/ml. 50 ml were mixed with equal volume of purified anti-
HBsAg antibody (50 ng/ml) from P. tricornutum and incubated for
1 h. Subsequently, 50 ml of the antigen-antibody mixture was
added to the wells and incubated for 2 h. Detection of bound
antibody was handled as described above. Commercially available
HBsAg was serially diluted and served as positive control in a wild
type protein extract background.
Fluorescence microscopy
In vivo localization of GFP fusion proteins was analysed with
confocal laser scanning microscopes Leica TCS SP2 and SP5
using a HCX PLAPO 636/1.32–0.6 oil Ph3 CS objective. GFP
and chlorophyll fluorescence was excited at 488 nm and detected
at a bandwidth of 500–520 nm and 625–720 nm, respectively.
CFP fluorescence was excited at 405 nm and detected with a
bandwidth of 430–480 nm.
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